Infection with the Human Immunodeficiency Virus Type 2
D. Markovitz
DOI: https://doi.org/10.7326/0003-4819-118-3-199302010-00010
IF: 39.2
1993-02-01
Annals of Internal Medicine
Abstract:The human immunodeficiency virus type 2 (HIV-2), like HIV-1, can cause the acquired immunodeficiency syndrome (AIDS) and related illnesses. Infection with HIV-2 is well recognized in West Africa, but persons infected with this human retrovirus are now being identified more frequently in other parts of the world. Although infection with HIV-2 is still rare in the United States, the Food and Drug Administration (FDA) has recently made the prudent decision to mandate testing of the blood supply for this agent. The HIV-2, which is more closely related to the simian immunodeficiency virus (SIV) than to HIV-1, appears to be less virulent than HIV-1, and has less efficient perinatal transmission. Further, HIV-2 is regulated differently than HIV-1 at the genetic level. Relationship to Other Human Retroviruses Although it has been recognized for years that retroviruses cause tumors in animals, the first clear link between human disease and retroviruses was reported in the early 1980s, when Gallo's group at the National Institutes of Health and Hinuma and coworkers in Japan discovered the link between the human T-cell leukemia virus type I (HTLV-I) and adult T-cell leukemia [1-4]. In addition, HTLV-I has subsequently been shown to be associated with tropical spastic paraparesis and similar myelopathies [5, 6]. The closely related retrovirus HTLV-II was first isolated from cell lines originating from patients with hairy cell leukemia [7-9]. However, although HTLV-II infection is now being recognized more frequently in the United States (particularly among groups such as intravenous drug abusers), HTLV-II has not yet been conclusively linked to any disease [10, 11]. From 1983 to 1984, it was shown that a newly discovered human retrovirus was a causative agent of AIDS [12-14]. This virus was first called HTLV-III by the American group and lymphadenopathy-associated virus (LAV) by the French group [15]. These two viruses have subsequently been shown to be essentially identical, and this virus, which demonstrates essentially no similarity to HTLV-I or HTLV-II at the genetic level, is now called the human immunodeficiency virus type 1. In 1985, Kanki, Essex, and coworkers described a group of healthy Senegalese whose sera demonstrated much stronger antibody responses to SIV than to HIV-1 [16, 17]. In 1986, Montagnier's group isolated a new retrovirus from West African patients with AIDS or AIDS-related complex [18-20]. The new virus belonged to the HIV group, but differed significantly from HIV-1 [18, 19]. Whereas different isolates of HIV-1 showed relatively minor antigenic variation, the West African virus, HIV-2, showed significant antigenic variation from HIV-1, with only limited serologic cross-reactivity [18, 19]. Analysis of the nucleotide sequence of this isolate of HIV-2 showed only 42% similarity to HIV-1 but 75% similarity to certain strains of SIV [21]. Although the genomic organization and the function of the gene products encoded by HIV-2 are very similar to HIV-1 [21], HIV-2 appears to differ in its biological properties when compared to HIV-1. Epidemiology of Human Immunodeficiency Virus Type 2 Infection Infection with HIV-2 was first described in urban settings in West Africa [20]. Indeed, HIV-2 appears to have been present in West Africa at least since 1966 [22, 23]. Moderate to high rates of infection have been found (Figure 1) in urban areas of Senegal, Guinea, Guinea-Bissau, Burkina Faso, Ivory Coast, Gambia, and Cape Verde [24, 25]. Interestingly, significant rates of HIV-2 infection have been reported in Angola and Mozambique (Figure 1), two countries located in southern Africa [25]. These countries were formerly Portuguese colonies and maintain ongoing relationships with countries in Western Africa (Guinea-Bissau, Cape Verde), which were also Portuguese colonies [25]. In Guinea-Bissau and Gambia, HIV-2 is the prevalent HIV, and HIV-1 is rare. In Ivory Coast and Burkina Faso, HIV-2 and HIV-1 are both present in an appreciable proportion of the population. In contrast, in Benin, infection with either virus is rare [26]. Like HIV-1, HIV-2 is transmitted sexually and, in Africa, this appears to be largely due to heterosexual transmission. In certain urban centers in West Africa, 15% to 64% of female prostitutes are infected [24]. Consistent with the idea that HIV-2 may be less virulent than HIV-1 and that HIV-2 has been present in West Africa for several generations, seropositivity increases with age in prostitutes in Dakar, Senegal, with almost 100% of 50-year-old prostitutes being infected [24, 25]. Figure 1. Distribution of HIV-2 in Africa. Infection with HIV-2 is now being recognized with increasing frequency in West Africa and other areas of the world [27-34]. Infected individuals have been identified in Europe [28, 31], North America [34, 35], and South America [29], although, where a history was obtained, the infected individual was generally from West Africa or had sexual contact with such a person. More recently, a pocket of HIV-2 infection has been identified in Bombay, India [36, 37]. Therefore, although HIV-2 infection probably originated in West Africa, it may, like HIV-1, come to pose a significant concern on other continents. The prevalence of HIV-2 infection in the United States is still low, with 32 cases reported to the Centers for Disease Control (CDC) as of April 1992 [38]. In all cases for which a history has been available, the infected individuals have previously lived in West Africa or have had sexual partners from that region. Until recently, the blood supply of the United States was not screened specifically for HIV-2. However, approximately 80% of sera from HIV-2 infected individuals cross-react in an HIV-1 enzyme immunosorbent assay (ELISA), and people from West Africa have been asked to refrain from donating blood. Indeed, no cases of transfusion-related HIV-2 infection have been discovered in the United States, consistent with these factors and the low prevalence of infection [39, 40]. As of June 1992, the FDA has mandated that blood banks must screen the blood supply for HIV-2. This prudent measure will further protect against HIV-2 infection resulting from a transfusion. However, transmission of HIV-2 to a larger percentage of the American population through sexual contact and shared needles is possible. Transmission Human immunodeficiency virus type 2 appears to be transmitted in West Africa principally by sexual contact, with prostitutes being the most well-studied group [24, 25, 33, 41]. The virus can also be spread by contact with infected blood, such as with transfusion [33]. Early evidence indicates that the transmission pattern of HIV-2 differs in at least one significant manner from that of HIV-1: Whereas at least 30% of babies born to mothers infected with HIV-1 are infected, no more than 10% of infants born to HIV-2-infected mothers appear to be infected [25, 42-44]. It has been theorized that the low rate of transmission may result from lower viral titers in the blood of HIV-2 patients compared with those infected with HIV-1. Preliminary data using polymerase chain reaction (PCR) and viral isolation indicates that viremia may be significantly lower in HIV-2 patients than in comparably staged HIV-1 patients (Kanki P. Personal communication). In addition, recent evidence indicates that only a particular subset of the subtypes of HIV-1 infecting a given mother are transmitted perinatally [45], but whether either of these findings will have a bearing on the issue of inefficient perinatal transmission of HIV-2 is also unknown. Clinical Course Early case reports clearly showed that HIV-2 can cause AIDS [20, 28, 33]. Because the period between infection and development of AIDS appears to be substantially longer than that for HIV-1 [25, 27, 42], prospective cohort studies have only recently begun to confirm this link [46]. Estimates indicate that the rate of progression to CDC stage IV disease is 3 to 4 times greater for HIV-1 than for HIV-2 and that the rate of progression to overt AIDS is 12 to 13 times greater [46]. Individuals infected by HIV-2 are, therefore, less likely to develop AIDS or, at least, will have a much longer asymptomatic period [25]. These estimated rates would further imply that progression of symptomatic disease to AIDS is slower for HIV-2 than for HIV-1. Once HIV-2-infected patients develop AIDS, progression to death may be slower than for HIV-1-infected AIDS patients [28], although this matter has not yet been thoroughly studied. Consistent with the slower clinical progression, other objective measurements of immunity appear to decline more slowly with HIV-2 infection than with HIV-1. Prostitutes in Senegal who are infected with HIV-2 are approximately twice as likely to show skin test anergy than are seronegative prostitutes. Those with HIV-1 infection are six times more likely to be anergic than are seronegative prostitutes, or three times more likely than those infected with HIV-2 [46]. Similarly, initial evaluation of HIV-2-infected persons has revealed T4 counts and T4/T8 ratios intermediate between those of uninfected individuals and those with HIV-1 infection [46, 47]. The symptoms resulting from infection with HIV-2 appear to be very similar to those caused by HIV-1 infection. As with HIV-1, HIV-2-related disease can be separated into two broad categories: symptoms caused primarily by the virus itself or symptoms caused by opportunistic infections or tumors resulting from the destruction of the immune system. Human immunodeficiency virus type 2 infection can cause diffuse lymphadenopathy, weight loss, and chronic diarrhea in the absence of any other identifiable pathogen [20, 27, 28, 33]. As with HIV-1, HIV-2 infection alone can also cause both central and peripheral nervous system disease [20, 48, 49]. The infectious mononucleosis-like syndrome of acute HIV-1 infection [50] has not yet been described for HIV-2, but this is probably due t